［1］GALLI G,PROTO C,SIGNORELLI D,et al.Characterization of patients with metastatic non-small-cell lung cancer obtaining long-term benefit from immunotherapy［J］.Future oncology(London,England),2019,15(23):2743-2757.
［2］WU Y,JU Q,JIA K,et al.Correlation between sex and efficacy of immune checkpoint inhibitors(PD-1 and CTLA-4 inhibitors)［J］.Int J Cancer,2018,143(1):45-51.
［3］CONFORTI F,PALA L,PAGAN E,et al.Sex-based differences in response to anti-PD-1 or PD-L1 treatment in patients with non-small-cell lung cancer expressing high PD-L1 levels.A systematic review and meta-analysis of randomized clinical trials［J］.ESMO Open,2021,6(5):100251.
［4］WALLIS CJD,BUTANEY M,SATKUNASIVAM R,et al.Association of patient sex with efficacy of immune checkpoint inhibitors and overall survival in advanced cancers:A systematic review and Meta-analysis［J］.JAMA Oncol,2019,5(4):529-536.
［5］XIAO D,PAN H,LI F,et al.Analysis of ultra-deep targeted sequencing reveals mutation burden is associated with gender and clinical outcome in lung adenocarcinoma［J］.Oncotarget,2016,7(16):22857-22864.
［6］LI CH,HAIDER S,SHIAH YJ,et al.Sex differences in cancer driver genes and biomarkers［J］.Cancer Res,2018,78(19):5527-5537.
［7］WANG S,COWLEY LA,LIU XS.Sex differences in cancer immunotherapy efficacy,biomarkers,and therapeutic strategy［J］.Molecules,2019,24(18):3214.
［8］ELIAS R,MORALES J,REHMAN Y,et al.Immune checkpoint inhibitors in older adults［J］.Curr Oncol Rep,2016,18(8):47.
［9］KSIENSKI D,WAI ES,CROTEAU NS,et al.Association of age with differences in immune related adverse events and survival of patients with advanced nonsmall cell lung cancer receiving pembrolizumab or nivolumab［J］.J Geriatr Oncol,2020,11(5):807-813.
［10］CORBAUX P,MAILLET D,BOESPFLUG A,et al.Older and younger patients treated with immune checkpoint inhibitors have similar outcomes in real-life setting［J］.Eur J Cancer,2019,121:192-201.
［11］LANDRE T,DES GUETZ G,CHOUAHNIA K,et al.Immune checkpoint inhibitors for patients aged ≥75 years with advanced cancer in first-and second-line settings:A Meta-analysis［J］.Drugs Aging,2020,37(10):747-754.
［12］SUN YM,WANG Y,SUN XX,et al.Clinical efficacy of immune checkpoint inhibitors in older non-small-cell lung cancer patients:A Meta-analysis［J］.Front Oncol,2020,10：558454.
［13］ELIAS R,KARANTANOS T,SIRA E,et al.Immunotherapy comes of age:Immune aging & checkpoint inhibitors［J］.J Geriatr Oncol,2017,8(3):229-235.
［14］CORTELLINI A,BERSANELLI M,BUTI S,et al.A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors:When overweight becomes favorable［J］.J Immunother Cancer,2019,7(1):57.
［15］ZHANG S,PEASE DF,KULKARNI AA,et al.Real-world outcomes and clinical predictors of immune checkpoint inhibitor monotherapy in advanced lung cancer［J］.Clin Med Insights Oncol,2021,15:7-34.
［16］CORTELLINI A,BERSANELLI M,SANTINI D,et al.Another side of the association between body mass index(BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1(PD-1)/ programmed cell death-ligand 1(PD-L1) checkpoint inhibitors:A multicentre analysis of immune-related adverse events［J］.Eur J Cancer,2020,128:17-26.
［17］HAN SJ,GLATMAN ZARETSKY A,ANDRADE-OLIVEIRA V,et al.White adipose tissue is a reservoir for memory T cells and promotes protective memory responses to infection［J］.Immunity,2017,47(6):1154-1168.
［18］WANG Z,AGUILAR EG,LUNA JI,et al.Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade［J］.Nat Med,2019,25(1):141-151.
［19］LI JJN,KARIM K,SUNG M,et al.Tobacco exposure and immunotherapy response in PD-L1 positive lung cancer patients［J］.Lung Cancer,2020,150:159-163.
［20］XU Y,WANG Q,XIE J,et al.The predictive value of clinical and molecular characteristics or immunotherapy in non-small cell lung cancer:A Meta-analysis of randomized controlled trials［J］.Front Oncol,2021,11:3605.
［21］XU Y,LI H,HUANG Z,et al.Predictive values of genomic variation,tumor mutational burden,and PD-L1 expression in advanced lung squamous cell carcinoma treated with immunotherapy［J］.Translational Lung Cancer Research,2020,9(6):2367-2379.
［22］WANG GZ,ZHANG L,ZHAO XC,et al.The aryl hydrocarbon receptor mediates tobacco-induced PD-L1 expression and is associated with response to immunotherapy［J］.Nat Commun,2019,10(1):1125.
［23］CHIU M,LIPKA MB,BHATEJA P,et al.A detailed smoking history and determination of MYC status predict response to checkpoint inhibitors in advanced non-small cell lung cancer［J］.Transl Lung Cancer Res,2020,9(1):55-60.
［24］WANG X,RICCIUTI B,ALESSI JV,et al.Smoking history as a potential predictor of immune checkpoint inhibitor efficacy in metastatic non-small cell lung cancer［J］.J Natl Cancer Inst,2021,113(12):1761-1769.
［25］RUSSO A,RUSSANO M,FRANCHINA T,et al.Neutrophil-to-lymphocyte ratio(NLR),platelet-to-lymphocyte ratio(PLR),and outcomes with nivolumab in pretreated non-small cell lung cancer(NSCLC):A large retrospective multicenter study［J］.Adv Ther,2020,37(3):1145-1155.
［26］AYERS KL,MA M,DEBUSSCHE G,et al.A composite biomarker of neutrophil-lymphocyte ratio and hemoglobin level correlates with clinical response to PD-1 and PD-L1 inhibitors in advanced non-small cell lung cancers［J］.BMC Cancer,2021,21(1):441.
［27］SANCHEZ-GASTALDO A,MUNOZ-FUENTES MA,MOLINA-PINELO S,et al.Correlation of peripheral blood biomarkers with clinical outcomes in NSCLC patients with high PD-L1 expression treated with pembrolizumab［J］.Transl Lung Cancer Res,2021,10(6):2509-2522.
［28］KAO C,POWERS E,WU Y,et al.Predictive value of combining biomarkers for clinical outcomes in advanced non-small cell lung cancer patients receiving immune checkpoint inhibitors［J］.Clin Lung Cancer,2021,22(6):500-509.
［29］PETROVA MP,ENEVA MI,ARABADJIEV JI,et al.Neutrophil to lymphocyte ratio as a potential predictive marker for treatment with pembrolizumab as a second line treatment in patients with non-small cell lung cancer［J］.Biosci Trends,2020,14(1):48-55.
［30］HASEGAWA T,YANAGITANI N,UTSUMI H,et al.Association of high neutrophil-to-lymphocyte ratio with poor outcomes of pembrolizumab therapy in high-PD-L1-expressing non-small cell lung cancer［J］.Anticancer Res,2019,39(12):6851-6857.
［31］HUANG Y,SHEN A.The prediction potential of neutrophil-to-lymphocyte ratio for the therapeutic outcomes of programmed death receptor-1/programmed death ligand 1 inhibitors in non-small cell lung cancer patients:A Meta-analysis［J］.Medicine(Baltimore),2020,99(34):e21718.
［32］ZHANG Z,LI Y,YAN X,et al.Pretreatment lactate dehydrogenase may predict outcome of advanced non small-cell lung cancer patients treated with immune checkpoint inhibitors:A Meta-analysis［J］.Cancer Med,2019,8(4):1467-1473.
［33］QIAO T,XIONG Y,FENG Y,et al.Inhibition of LDH-A by oxamate enhances the efficacy of anti-PD-1 treatment in an NSCLC humanized mouse model［J］.Front Oncol,2021,11：632364.
［34］BENITEZ JC,RECONDO G,RASSY E,et al.The LIPI score and inflammatory biomarkers for selection of patients with solid tumors treated with checkpoint inhibitors［J］.Q J Nucl Med Mol Imaging,2020,64(2):162-174.
［35］ZER A,SUNG MR,WALIA P,et al.Correlation of neutrophil to lymphocyte ratio and absolute neutrophil count with outcomes with PD-1 axis inhibitors in patients with advanced non-small-cell lung cancer［J］.Clin Lung Cancer,2018,19(5):426-434.
［36］KAUFFMANN-GUERRERO D,KAHNERT K,KIEFL R,et al.Systemic inflammation and pro-inflammatory cytokine profile predict response to checkpoint inhibitor treatment in NSCLC:A prospective study［J］.Sci Rep,2021,11(1):10919.
［37］HARATANI K,HAYASHI H,CHIBA Y,et al.Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer［J］.JAMA Oncol,2018,4(3):374-378.
［38］OSORIO JC,NI A,CHAFT JE,et al.Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer［J］.Ann Oncol,2017,28(3):583-589.
［39］MIN LEE CK,LI S,TRAN DC,et al.Characterization of dermatitis after PD-1/PD-L1 inhibitor therapy and association with multiple oncologic outcomes:A retrospective case-control study［J］.J Am Acad Dermatol,2018,79(6):1047-1052.
［40］JIANG T,BAI Y,ZHOU F,et al.Clinical value of neutrophil-to-lymphocyte ratio in patients with non-small-cell lung cancer treated with PD-1/PD-L1 inhibitors［J］.Lung Cancer,2019,130:76-83.